𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II study of high-dose medroxyprogesterone acetate in advanced malignant melanoma

✍ Scribed by Becher, R; Kloke, O; Höffken, K; Scheulen, ME; Wandl, UB; Bojar, H; Schmidt, CG

Book ID
109836168
Publisher
Nature Publishing Group
Year
1989
Tongue
English
Weight
168 KB
Volume
59
Category
Article
ISSN
0007-0920

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II study of high-dose medroxypro
A phase II study of high-dose medroxyprogesterone acetate in advanced breast cancer
✍ Geoffrey Falkson; Hèndré C. Falkson 📂 Article 📅 1983 🏛 Springer 🌐 English ⚖ 215 KB

Twenty-three evaluable patients with advanced breast cancer were treated with MPA, 1,400 mg/m2 daily PO for the first 6 months, and 500 mg/m2 daily PO thereafter. The median total dose was 191,400 mg in 88 days, with the maximum dose given to date 522,600 mg in 282 days. Most patients tolerated high

Phase II study of high-dose tamoxifen (N
Phase II study of high-dose tamoxifen (NSC-180973) in patients with disseminated malignant melanoma
✍ Edward T. Creagan; James N. Ingle; David L. Ahmann; Stephanie J. Green 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 206 KB 👁 3 views

Seventeen patients with disseminated malignant melanoma received a daily oral regimen of tamoxifen, 100 mg/m2. All patients had prior chemotherapy and predominantly visceral involvement. None of the patients had an objective regression and most (71%) had progressive disease at the time of first reas